Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXG102-031 Long-term Follow-Up in nAMD
NCT06817343Phase 1Active, not recruiting
- Sponsor
- Exegenesis Bio
- Start
- Sep 2024
- Primary completion
- Feb 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EXG102 in neovascular age-related macular degeneration (NVAMD), sponsored by Exegenesis Bio. Primary endpoint: Adverse Events and Serious Adverse Events at 36 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
EXG102
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06817343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06817343.